Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro

被引：19
|
作者：
Xiong, Hua-Long [1 ,2 ]
Cao, Jia-Li [1 ,2 ,3 ]
Shen, Chen-Guang [4 ,5 ]
Ma, Jian [1 ,2 ]
Qiao, Xiao-Yang [1 ,2 ]
Shi, Tian-Shu [1 ,2 ]
Ge, Sheng-Xiang [1 ,2 ]
Ye, Hui-Ming [2 ,3 ]
Zhang, Jun [1 ,2 ]
Yuan, Quan [1 ,2 ]
Zhang, Tian-Ying [1 ,2 ]
Xia, Ning-Shao [1 ,2 ]
机构：
[1] Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, Sch Life Sci, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Peoples R China
[2] Xiamen Univ, Sch Publ Hlth, Xiamen, Peoples R China
[3] Xiamen Univ, Sch Med, Women & Childrens Hosp, Dept Clin Lab, Xiamen, Peoples R China
[4] Southern Univ Sci & Technol, State Key Discipline Infect Dis, Hosp Affiliated 2,Shenzhen Peoples Hosp 3, Shenzhen Key Lab Pathogen & Immun,Natl Clin Res C, Shenzhen, Peoples R China
[5] Southern Med Univ, Sch Publ Hlth, Guangzhou, Peoples R China
来源：
FRONTIERS IN PHARMACOLOGY | 2021年 / 11卷
基金：
中国国家自然科学基金;
关键词：
drug screening; SARS-CoV-2; pseudovirus assay; vesicular stomatitis virus; drug combination; ENTRY;
D O I：
10.3389/fphar.2020.609592
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
To identify drugs that are potentially used for the treatment of COVID-19, the potency of 1403 FDA-approved drugs were evaluated using a robust pseudovirus assay and the candidates were further confirmed by authentic SARS-CoV-2 assay. Four compounds, Clomiphene (citrate), Vortioxetine, Vortioxetine (hydrobromide) and Asenapine (hydrochloride), showed potent inhibitory effects in both pseudovirus and authentic virus assay. The combination of Clomiphene (citrate), Vortioxetine and Asenapine (hydrochloride) is much more potent than used alone, with IC50 of 0.34 mu M.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease
    Mandour, Yasmine M.
    Zlotos, Darius P.
    Salem, M. Alaraby
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (05): : 2327 - 2338
  • [22] Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2
    Liang, Hualou
    Zhao, Liang
    Gong, Xiajing
    Hu, Meng
    Wang, Hongbin
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (03): : 1123 - 1132
  • [23] Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
    Joel, C.
    Jebakumar, D. S. Ivan
    Bennie, R. Biju
    Ebenezer, Cheriyan
    Solomon, Rajadurai Vijay
    Abraham, S. Daniel
    IRANIAN JOURNAL OF SCIENCE, 2023, 47 (03) : 617 - 630
  • [24] Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen
    Taha, Zaid
    Arulanandam, Rozanne
    Maznyi, Glib
    Godbout, Elena
    Carter-Timofte, Madalina E.
    Kurmasheva, Naziia
    Reinert, Line S.
    Chen, Andrew
    Crupi, Mathieu J. F.
    Boulton, Stephen
    Laroche, Genevieve
    Phan, Alexandra
    Rezaei, Reza
    Alluqmani, Nouf
    Jirovec, Anna
    Acal, Alexandra
    Fekete, Emily E. F.
    Singaravelu, Ragunath
    Petryk, Julia
    Idorn, Manja
    Potts, Kyle G.
    Todesco, Hayley
    John, Cini
    Mahoney, Douglas J.
    Ilkow, Carolina S.
    Giguere, Patrick
    Alain, Tommy
    Cote, Marceline
    Paludan, Soren R.
    Olagnier, David
    Bell, John C.
    Azad, Taha
    Diallo, Jean-Simon
    MOLECULAR THERAPY, 2022, 30 (09) : 2998 - 3016
  • [25] Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
    C. Joel
    D. S. Ivan Jebakumar
    R. Biju Bennie
    Cheriyan Ebenezer
    Rajadurai Vijay Solomon
    S. Daniel Abraham
    Iranian Journal of Science, 2023, 47 : 617 - 630
  • [26] Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation
    Gendrot, Mathieu
    Andreani, Julien
    Boxberger, Manon
    Jardot, Priscilla
    Fonta, Isabelle
    Le Bideau, Marion
    Duflot, Isabelle
    Mosnier, Joel
    Rolland, Clara
    Bogreau, Herve
    Hutter, Sebastien
    La Scola, Bernard
    Pradines, Bruno
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2020, 37
  • [27] The nsp15 nuclease as a good target to combat SARS-CoV-2: mechanism of action and its inactivation with FDA-approved drugs
    Saramago, M.
    Costa, V. G.
    Souza, C. S.
    Barria, C.
    Domingues, S.
    Viegas, S. C.
    Lousa, D.
    Soares, C. M.
    Arraiano, C. M.
    Matos, R. G.
    FEBS OPEN BIO, 2022, 12 : 286 - 286
  • [28] Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
    Fu, Wenyu
    Chen, Yujianan
    Wang, Kaidi
    Hettinghouse, Aubryanna
    Hu, Wenhuo
    Wang, Jing-Quan
    Lei, Zi-Ning
    Chen, Zhe-Sheng
    Stapleford, Kenneth A.
    Liu, Chuan-ju
    PROTEIN & CELL, 2021, 12 (07) : 586 - 591
  • [29] Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
    Wenyu Fu
    Yujianan Chen
    Kaidi Wang
    Aubryanna Hettinghouse
    Wenhuo Hu
    JingQuan Wang
    ZiNing Lei
    ZheSheng Chen
    Kenneth AStapleford
    Chuanju Liu
    Protein & Cell, 2021, 12 (07) : 586 - 591
  • [30] The nsp15 Nuclease as a Good Target to Combat SARS-CoV-2: Mechanism of Action and Its Inactivation with FDA-Approved Drugs
    Saramago, Margarida
    Costa, Vanessa G.
    Souza, Caio S.
    Barria, Catia
    Domingues, Susana
    Viegas, Sandra C.
    Lousa, Diana
    Soares, Claudio M.
    Arraiano, Cecilia M.
    Matos, Rute G.
    MICROORGANISMS, 2022, 10 (02)
12345